Skip to main content
Top
Published in: Diabetologia 8/2007

01-08-2007 | For debate

Changing perspectives in diabetes: their impact on its classification

Author: T. J. Wilkin

Published in: Diabetologia | Issue 8/2007

Login to get access

Abstract

Type 1 and type 2 diabetes are usually regarded as distinct disorders, but the convergence of their phenotypes over recent years, the relationship of body weight to the risk of type 1 diabetes, the diminishing importance of the type 1 susceptibility genes and the finding of autoantibodies in patients with type 2 diabetes, invite a different interpretation. The possibility that type 1 and type 2 diabetes, rather than being different, are merely poles of a single spectrum, where variation in the tempo of beta cell loss determines age at onset and symptoms at presentation, has important implications. Correct classification is crucial because it directs appropriate treatment and, where available, prevention. This article argues that type 1 diabetes is currently misclassified, provides evidence that insulin resistance drives type 1 diabetes as it does type 2, and proposes how the ‘accelerator hypothesis’ can be tested in a randomised controlled trial, which could demonstrate, for the first time, the safe and effective prevention of type 1 diabetes.
Literature
1.
go back to reference Gepts W (1965) Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14:619–633PubMed Gepts W (1965) Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14:619–633PubMed
2.
3.
go back to reference Bottazzo GF, Florin-Christensen A, Doniach D (1974) Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2:1279–1283PubMedCrossRef Bottazzo GF, Florin-Christensen A, Doniach D (1974) Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2:1279–1283PubMedCrossRef
4.
go back to reference Irvine WJ, McCallum CJ, Gray RS, Duncan LJ (1977) Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet 1:1025–1027PubMedCrossRef Irvine WJ, McCallum CJ, Gray RS, Duncan LJ (1977) Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet 1:1025–1027PubMedCrossRef
6.
go back to reference Tuomi T, Groop LC, Zimmet PZ, Rowley, MJ, Knowles W, Mackay IR (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359–362PubMedCrossRef Tuomi T, Groop LC, Zimmet PZ, Rowley, MJ, Knowles W, Mackay IR (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359–362PubMedCrossRef
7.
go back to reference Molbak AG, Christau B, Marner B, Borch-Johnsen K, Nerup J (1994) Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark. Diabet Med 11:650–655PubMedCrossRef Molbak AG, Christau B, Marner B, Borch-Johnsen K, Nerup J (1994) Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark. Diabet Med 11:650–655PubMedCrossRef
8.
go back to reference Caillat-Zucman S, Garchon HJ, Timsit J et al (1992) Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest 90:2242–2250PubMedCrossRef Caillat-Zucman S, Garchon HJ, Timsit J et al (1992) Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest 90:2242–2250PubMedCrossRef
9.
go back to reference Rosenbloom AL, Joe JR, Young RS, Winter WE (1999) Emerging epidemic of type 2 diabetes in youth. Diabetes Care 22:345–354PubMedCrossRef Rosenbloom AL, Joe JR, Young RS, Winter WE (1999) Emerging epidemic of type 2 diabetes in youth. Diabetes Care 22:345–354PubMedCrossRef
10.
go back to reference Etisham S, Barrett TG (2004) The emergence of type 2 diabetes in childhood. Ann Clin Biochem 41:10–16CrossRef Etisham S, Barrett TG (2004) The emergence of type 2 diabetes in childhood. Ann Clin Biochem 41:10–16CrossRef
11.
go back to reference Karvonen M, Pitkaniemi J, Tuomilehto J (1999) The onset age of type 1 diabetes in Finnish children has become younger. (The Finnish Childhood Diabetes Registry Group). Diabetes Care 22:1066–1070PubMedCrossRef Karvonen M, Pitkaniemi J, Tuomilehto J (1999) The onset age of type 1 diabetes in Finnish children has become younger. (The Finnish Childhood Diabetes Registry Group). Diabetes Care 22:1066–1070PubMedCrossRef
12.
go back to reference Gale EAM (2002) The rise of childhood diabetes in the twentieth century. Diabetes 12:3353–3361CrossRef Gale EAM (2002) The rise of childhood diabetes in the twentieth century. Diabetes 12:3353–3361CrossRef
13.
14.
go back to reference Brooks-Worrell BM, Greenbaum CJ, Palmer JP, Pihoker C (2004) Autoimmunity to islet proteins in children diagnosed with new-onset diabetes. J Clin Endocrinol Metab 89:2222–2227PubMedCrossRef Brooks-Worrell BM, Greenbaum CJ, Palmer JP, Pihoker C (2004) Autoimmunity to islet proteins in children diagnosed with new-onset diabetes. J Clin Endocrinol Metab 89:2222–2227PubMedCrossRef
15.
go back to reference Betts P, Mulligan J, Ward P, Smith B, Wilkin T (2005) Increasing body weight predicts the earlier onset of insulin-dependent diabetes in childhood: testing the ‘accelerator hypothesis’ (2). Diabet Med 22:144–151PubMedCrossRef Betts P, Mulligan J, Ward P, Smith B, Wilkin T (2005) Increasing body weight predicts the earlier onset of insulin-dependent diabetes in childhood: testing the ‘accelerator hypothesis’ (2). Diabet Med 22:144–151PubMedCrossRef
16.
go back to reference Heinze E, Thon A (1985) Honeymoon period in insulin-dependent diabetes mellitus. Pediatrician 12:208–212 Heinze E, Thon A (1985) Honeymoon period in insulin-dependent diabetes mellitus. Pediatrician 12:208–212
18.
go back to reference Babaya N, Nakayama M, Eisenbarth GS (2005) The stages of type 1A diabetes. Ann N Y Acad Sci 1051:194–204PubMedCrossRef Babaya N, Nakayama M, Eisenbarth GS (2005) The stages of type 1A diabetes. Ann N Y Acad Sci 1051:194–204PubMedCrossRef
19.
go back to reference Maugendre D, Alizadeh M, Gauthier A et al (1996) Genetic heterogeneity between type 1a and type 1b insulin-dependent diabetes mellitus: HLA class II and TAP gene analysis. Tissue Antigens 48:540–548PubMed Maugendre D, Alizadeh M, Gauthier A et al (1996) Genetic heterogeneity between type 1a and type 1b insulin-dependent diabetes mellitus: HLA class II and TAP gene analysis. Tissue Antigens 48:540–548PubMed
20.
go back to reference Owen K, Hattersley AT (2001) Maturity-onset diabetes of the young: from clinical description to molecular genetic characterization. Best Pract Res Clin Endocrinol Metab 15:309–323PubMedCrossRef Owen K, Hattersley AT (2001) Maturity-onset diabetes of the young: from clinical description to molecular genetic characterization. Best Pract Res Clin Endocrinol Metab 15:309–323PubMedCrossRef
21.
go back to reference Libman IM, Becker DJ (2003) Coexistence of type 1 and type 2 diabetes mellitus: “double” diabetes? Pediatr Diabetes 4:110–113PubMedCrossRef Libman IM, Becker DJ (2003) Coexistence of type 1 and type 2 diabetes mellitus: “double” diabetes? Pediatr Diabetes 4:110–113PubMedCrossRef
22.
go back to reference Reinehr T, Schober E, Wiegand S, Thon A, Holl R (2006) Beta-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? Arch Dis Child 91:473–477PubMedCrossRef Reinehr T, Schober E, Wiegand S, Thon A, Holl R (2006) Beta-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? Arch Dis Child 91:473–477PubMedCrossRef
23.
go back to reference Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A (2001) Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 50(Suppl 1):8154–8159 Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A (2001) Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 50(Suppl 1):8154–8159
24.
go back to reference Prentice AM (1997) Obesity—the inevitable penalty of civilisation? Br Med Bull 53:229–237PubMed Prentice AM (1997) Obesity—the inevitable penalty of civilisation? Br Med Bull 53:229–237PubMed
25.
go back to reference Bundred P, Kitchiner D, Buchan I (2001) Prevalence of overweight and obese children between 1989 and 1998: population based series of cross sectional studies. BMJ 322:326–328PubMedCrossRef Bundred P, Kitchiner D, Buchan I (2001) Prevalence of overweight and obese children between 1989 and 1998: population based series of cross sectional studies. BMJ 322:326–328PubMedCrossRef
26.
go back to reference Budde P, Schulte I, Appel A et al (2005) Peptidomics biomarker discovery in mouse models of obesity and type 2 diabetes. Comb Chem High Throughput Screen 8:775–781PubMedCrossRef Budde P, Schulte I, Appel A et al (2005) Peptidomics biomarker discovery in mouse models of obesity and type 2 diabetes. Comb Chem High Throughput Screen 8:775–781PubMedCrossRef
27.
go back to reference Wilkin TJ (2001) The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 44:914–922PubMedCrossRef Wilkin TJ (2001) The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 44:914–922PubMedCrossRef
28.
go back to reference Tuomilheto-Wolf E, Tuomilheto J, Hitman GA et al (1993) Genetic susceptibility to non-insulin-dependent diabetes mellitus and glucose intolerance are located in the HLA region. BMJ 307:155–159CrossRef Tuomilheto-Wolf E, Tuomilheto J, Hitman GA et al (1993) Genetic susceptibility to non-insulin-dependent diabetes mellitus and glucose intolerance are located in the HLA region. BMJ 307:155–159CrossRef
29.
go back to reference Voss LD, Kirkby J, Metcalf BS et al (2003) Preventable factors in childhood that lead to insulin resistance, diabetes mellitus and the metabolic syndrome (EarlyBird 1). J Pediatr Endocrinol Metab 16:1211–1224PubMed Voss LD, Kirkby J, Metcalf BS et al (2003) Preventable factors in childhood that lead to insulin resistance, diabetes mellitus and the metabolic syndrome (EarlyBird 1). J Pediatr Endocrinol Metab 16:1211–1224PubMed
30.
go back to reference Baum JD, Ounsted M, Smith MA (1975) Weight gain in infancy and subsequent development of diabetes mellitus in childhood. Lancet 2:866PubMedCrossRef Baum JD, Ounsted M, Smith MA (1975) Weight gain in infancy and subsequent development of diabetes mellitus in childhood. Lancet 2:866PubMedCrossRef
31.
go back to reference Johansson C, Samuelsson U, Ludvigsson J (1994) A high weight gain in early life is associated with an increased risk of type 1 (insulin-dependent) diabetes. Diabetologia 37:91–94PubMed Johansson C, Samuelsson U, Ludvigsson J (1994) A high weight gain in early life is associated with an increased risk of type 1 (insulin-dependent) diabetes. Diabetologia 37:91–94PubMed
32.
go back to reference Hypponen E, Kenward MG, Virtanen SM et al (1999) Infant feeding, early weight gain and risk of type 1 diabetes. Diabetes Care 22:1961–1965PubMedCrossRef Hypponen E, Kenward MG, Virtanen SM et al (1999) Infant feeding, early weight gain and risk of type 1 diabetes. Diabetes Care 22:1961–1965PubMedCrossRef
33.
go back to reference Bruining GJ (2000) Association between infant growth before onset of juvenile type-1 diabetes and autoantibodies to IA-2. (Netherlands Kolibrie study group of childhood diabetes). Lancet 356:655–656PubMedCrossRef Bruining GJ (2000) Association between infant growth before onset of juvenile type-1 diabetes and autoantibodies to IA-2. (Netherlands Kolibrie study group of childhood diabetes). Lancet 356:655–656PubMedCrossRef
34.
go back to reference Hypponen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK (2000) Obesity, increased linear growth, and risk of type 1 diabetes in children. (Childhood Diabetes in Finland Study Group). Diabetes Care 23:1755–1760PubMedCrossRef Hypponen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK (2000) Obesity, increased linear growth, and risk of type 1 diabetes in children. (Childhood Diabetes in Finland Study Group). Diabetes Care 23:1755–1760PubMedCrossRef
35.
go back to reference Kibirige M, Metcalf B, Renuka R, Wilkin TJ (2003) Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 26:2865–2870PubMedCrossRef Kibirige M, Metcalf B, Renuka R, Wilkin TJ (2003) Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 26:2865–2870PubMedCrossRef
36.
go back to reference Knerr I, Wolf J, Reinehr T, Stachow R et al (2005) The ‘accelerator hypothesis’: relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9,248 German and Austrian children with type 1 diabetes mellitus. Diabetologia 48:2501–2504PubMedCrossRef Knerr I, Wolf J, Reinehr T, Stachow R et al (2005) The ‘accelerator hypothesis’: relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9,248 German and Austrian children with type 1 diabetes mellitus. Diabetologia 48:2501–2504PubMedCrossRef
37.
go back to reference Kordonouri O, Hartmann R (2005) Higher body weight is associated with earlier onset of type 1 diabetes in children: confirming the ‘accelerator hypothesis’. Diabet Med 22:1783–1784PubMedCrossRef Kordonouri O, Hartmann R (2005) Higher body weight is associated with earlier onset of type 1 diabetes in children: confirming the ‘accelerator hypothesis’. Diabet Med 22:1783–1784PubMedCrossRef
38.
go back to reference Dabelea D, D’Agostino RB Jr, Mayer-Davis EJ et al (2006) SEARCH for Diabetes in Youth Study Group. Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care 29:290–294PubMedCrossRef Dabelea D, D’Agostino RB Jr, Mayer-Davis EJ et al (2006) SEARCH for Diabetes in Youth Study Group. Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care 29:290–294PubMedCrossRef
39.
go back to reference Hermann R, Knip M, Veijola R (2003) Temporal changes in the frequencies of HLA genotypes in patients with type I diabetes–indication of an increased environmental pressure? Diabetologia 46:420–425PubMed Hermann R, Knip M, Veijola R (2003) Temporal changes in the frequencies of HLA genotypes in patients with type I diabetes–indication of an increased environmental pressure? Diabetologia 46:420–425PubMed
40.
go back to reference Gillespie KM, Bain SC, Barnett AH et al (2004) The rising incidence of type 1 diabetes is associated with a reduced contribution from high-risk HLA haplotypes. Lancet 364:1699–1700PubMedCrossRef Gillespie KM, Bain SC, Barnett AH et al (2004) The rising incidence of type 1 diabetes is associated with a reduced contribution from high-risk HLA haplotypes. Lancet 364:1699–1700PubMedCrossRef
41.
go back to reference Scholin A, Torn C, Nystrom L et al (2004) Normal weight promotes remission and low number of islet antibodies prolong the duration of remission in type 1 diabetes. Diabet Med 21:447–455PubMedCrossRef Scholin A, Torn C, Nystrom L et al (2004) Normal weight promotes remission and low number of islet antibodies prolong the duration of remission in type 1 diabetes. Diabet Med 21:447–455PubMedCrossRef
42.
go back to reference Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC (2004) Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 47:1661–1667PubMedCrossRef Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC (2004) Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 47:1661–1667PubMedCrossRef
43.
go back to reference Hawa Ml, Bonfanti R, Valeri C, Delli Castelli M, Beyan H, Leslie RD (2005) No evidence for genetically determined alteration in insulin secretion or sensitivity predisposing to type 1 diabetes: a study of identical twins. Diabetes Care 28:1415–1418PubMedCrossRef Hawa Ml, Bonfanti R, Valeri C, Delli Castelli M, Beyan H, Leslie RD (2005) No evidence for genetically determined alteration in insulin secretion or sensitivity predisposing to type 1 diabetes: a study of identical twins. Diabetes Care 28:1415–1418PubMedCrossRef
44.
go back to reference Wilkin TJ, Metcalf B, Jeffery A, Howdle S, Kirkby J, Voss LD (2002) The relative contributions of birth weight, catch-up weight and current weight to the development of insulin resistance in contemporary children (EarlyBird 2). Diabetes 51:3468–3472PubMedCrossRef Wilkin TJ, Metcalf B, Jeffery A, Howdle S, Kirkby J, Voss LD (2002) The relative contributions of birth weight, catch-up weight and current weight to the development of insulin resistance in contemporary children (EarlyBird 2). Diabetes 51:3468–3472PubMedCrossRef
45.
go back to reference Gungor N, Saad R, Janosky J, Arslanian S (2004) Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J Pediatr 144:47–55PubMedCrossRef Gungor N, Saad R, Janosky J, Arslanian S (2004) Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J Pediatr 144:47–55PubMedCrossRef
46.
go back to reference Chaparro RJ, Konigshofer Y, Beilhack GF, Shizuru JA, McDevitt HO, Chien HY (2006) Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. Proc Natl Acad Sci USA 103:12475–12480PubMedCrossRef Chaparro RJ, Konigshofer Y, Beilhack GF, Shizuru JA, McDevitt HO, Chien HY (2006) Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. Proc Natl Acad Sci USA 103:12475–12480PubMedCrossRef
47.
go back to reference Gale EA, Bingley PJ, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group (2006) Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 49:881–890PubMedCrossRef Gale EA, Bingley PJ, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group (2006) Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 49:881–890PubMedCrossRef
48.
go back to reference Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598–2608PubMedCrossRef Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598–2608PubMedCrossRef
49.
go back to reference Wilkin TJ, Ludvigsson J, Greenbaum CJ, Palmer JP, Becker DJ, Bruining J (2004) Future trials for the prevention of type 1 diabetes. Diabetes Care 27:996–997PubMedCrossRef Wilkin TJ, Ludvigsson J, Greenbaum CJ, Palmer JP, Becker DJ, Bruining J (2004) Future trials for the prevention of type 1 diabetes. Diabetes Care 27:996–997PubMedCrossRef
50.
go back to reference Wilkin TJ (2006) The great weight gain experiment, accelerators and their implications for autoantibodies in diabetes. Arch Dis Child 91:456–458PubMedCrossRef Wilkin TJ (2006) The great weight gain experiment, accelerators and their implications for autoantibodies in diabetes. Arch Dis Child 91:456–458PubMedCrossRef
Metadata
Title
Changing perspectives in diabetes: their impact on its classification
Author
T. J. Wilkin
Publication date
01-08-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0665-5

Other articles of this Issue 8/2007

Diabetologia 8/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.